{"id":"peg-interferon-a-2b-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Insomnia"},{"rate":"20-30","effect":"Nausea"},{"rate":"10-15","effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1201558","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PEG-Interferon alfa-2b is a pegylated form of interferon that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory responses including upregulation of MHC molecules and activation of natural killer cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing hepatitis C virus replication. The combination has synergistic antiviral activity against HCV.","oneSentence":"PEG-Interferon alfa-2b activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:04.579Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT00215891","phase":"PHASE3","title":"PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon","status":"COMPLETED","sponsor":"Hepatitis Resource Network","startDate":"","conditions":"Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections","enrollment":300},{"nctId":"NCT00215865","phase":"PHASE3","title":"PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy","status":"COMPLETED","sponsor":"Hepatitis Resource Network","startDate":"","conditions":"Chronic Hepatitis C Virus Infection","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PEG-Interferon a-2b + Ribavirin","genericName":"PEG-Interferon a-2b + Ribavirin","companyName":"Hepatitis Resource Network","companyId":"hepatitis-resource-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-Interferon alfa-2b activates innate immune responses against hepatitis C virus, while ribavirin inhibits viral replication through multiple mechanisms including nucleotide synthesis disruption. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}